Amgen to buy Onyx for $10.4 billion
Amgen plans to acquire oncology specialist Onyx Pharmaceuticals Inc. in a deal valued at $10.4 billion overall. Under the acquisition agreement, announced Sunday evening, Amgen will purchase all of the outstanding shares of Onyx at $125 per share in cash. Net of estimated Onyx cash, the purchase